Archives
-
Cy5-UTP for Practical RNA Probe Synthesis
2026-08-31
Cy5-UTP converts T7 in vitro transcription into a direct, far-red RNA detection workflow for FISH, expression arrays, and RNA interaction assays. This guide connects probe design and fluorescence optimization with the sequence-dependent RNA interactions revealed in a 2025 MALAT1 study.
-
HyperScript RT SuperMix: Assay Design for HCC
2026-08-31
HyperScript RT SuperMix for qPCR supports structurally challenging RNA and low-input cDNA synthesis for qPCR. This article connects reverse-transcription design with the multi-scale BIRC5–Hippo pathway investigation of hepatocellular carcinoma, emphasizing assay validity rather than product claims alone.
-
Protease Inhibitor Cocktail for Plant Protein Stability
2026-08-30
Protect fragile plant lysates from multi-class proteolysis while preserving phosphorylated and non-phosphorylated targets for Western blotting, co-immunoprecipitation, and kinase assays. This EDTA-free, DMSO-based formulation is especially useful when metal-dependent protein interactions or downstream enzymatic activity must remain intact.
-
LNP mRNA Bleb Structures and Transfection Potency
2026-08-29
The reference study shows that mRNA-rich bleb structures in lipid nanoparticles can be induced through formulation conditions, not only through ionizable-lipid optimization. High-concentration pH 4 sodium citrate improved transfection by preserving encapsulated mRNA, providing a practical formulation variable for both in vitro and in vivo studies.
-
Piroxicam and Deracoxib in Canine Mammary Cancer
2026-08-28
The reference study tested whether piroxicam and deracoxib could directly suppress CMT-U27 canine mammary carcinoma cells and whether combined exposure altered the mechanism of cell death. Using MTT viability testing and flow cytometry, the authors identified stronger combination-associated cytotoxicity, apoptosis, and G0/G1 accumulation, while also highlighting the limits of extrapolating high-concentration in vitro findings to clinical treatment.
-
A Broad-Spectrum mRNA Vaccine for Omicron and SARS-CoV
2026-08-28
Guan and colleagues developed a lipid nanoparticle-encapsulated mRNA vaccine that replaces the mutation-prone Omicron receptor-binding domain with a conserved SARS-CoV RBD. In mice, this chimeric design generated cross-reactive neutralizing antibodies and protection against both SARS-CoV-2 Omicron and SARS-CoV, supporting antigen engineering as a strategy for broader coronavirus vaccine coverage.
-
Angiotensin Peptides and SARS-CoV-2 Spike Binding
2026-08-27
The 2025 reference study reports that naturally occurring angiotensin peptides can increase SARS-CoV-2 spike-protein binding to host receptors, with the strongest effects associated with shorter, N-terminally truncated peptides such as angiotensin IV. Its antibody-based binding experiments identify peptide length and Tyr4 modification as important variables, while also emphasizing that biochemical binding does not establish enhanced viral infection in cells or patients.
-
NPT1-Mediated Faropenem Transport in Kidney
2026-08-27
The 2000 reference study provided the first molecular evidence that human NPT1, a renal apical sodium–phosphate transporter, can mediate p-aminohippuric acid and several organic anions, including faropenem. Its heterologous-cell uptake model established a mechanistic link between renal apical transport and β-lactam disposition while also defining important limits for interpreting antimicrobial or pharmacokinetic outcomes.
-
Pseudo-UTP: An Assay-First Guide to RNA Design
2026-08-26
Pseudo-UTP enables mRNA synthesis with pseudouridine modification, but its value depends on decisions made across transcription, purification, and functional testing. This assay-first guide connects nucleotide chemistry with translational evidence and practical quality controls.
-
Bivalent mRNA Vaccine Broadens SARS-CoV-2 Coverage
2026-08-26
The reference study evaluates RQ3025, a bivalent mRNA vaccine designed to present mutation patterns shared across evolving SARS-CoV-2 variants. Across several animal models, the construct induced broad neutralizing antibodies, provided protection against multiple variants, promoted a Th1-biased response, and showed no evident histopathological toxicity under the reported high-dose assessment.
-
Tranexamic Acid for Reliable Cell Assays
2026-08-25
Tranexamic Acid (SKU B1858) offers a defined, water-soluble approach to inhibition of fibrinolysis in cell-adherence, wound-model, and clot-stability workflows. This scenario-based guide explains concentration selection, assay controls, fresh-solution handling, interpretation limits, and practical product-quality criteria for reproducible fibrinolysis research.
-
Pseudo-UTP for Translational mRNA Assay Design
2026-08-25
Pseudo-UTP enables mRNA synthesis with pseudouridine modification, but its greatest value depends on disciplined assay design. This article connects nucleotide chemistry with mRNA-LNP immunotherapy research and shows how to separate RNA-quality effects from payload-specific biology.
-
AZD2461: Novel PARP Inhibitor Workflow Guide
2026-08-24
AZD2461 is a novel PARP inhibitor for dissecting DNA repair, cytostasis, cell death, and resistance in breast cancer models. This workflow emphasizes time-resolved assays and matched viability metrics so researchers can distinguish true killing from growth suppression and evaluate activity in Pgp-associated resistance settings.
-
CAIPS: AI Prognostic Modeling for HCC
2026-08-24
The reference study developed a consensus artificial intelligence-derived prognostic signature (CAIPS) for hepatocellular carcinoma by integrating 101 machine-learning strategies across six multi-center cohorts. Its seven-gene model improved risk stratification, associated molecular risk with treatment responsiveness, and identified candidate therapeutic and mechanistic priorities for precision oncology.
-
Talabostat Mesylate: Applied Research Workflows
2026-08-23
Talabostat mesylate, also called PT-100 or Val-boroPro, enables coordinated interrogation of DPP4 and FAP biology in cancer, immune, and hematopoietic models. This practical guide connects target-engagement assays with tumor microenvironment experiments, while using a recent epidermal homeostasis study to sharpen barrier-focused assay design without overstating cross-domain evidence.